Adamis Pharma (GB:0A4X)

Adamis Pharma (0A4X) Income Statement


Adamis Pharma Income Statement

Last quarter (Q1 2023), Adamis Pharma's total revenue was $1.45M, an increase of 25.85% from the same quarter last year. In Q1, Adamis Pharma's net income was $6.82M. See Adamis Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 5.05M$ 4.76M$ 2.21M$ 2.78M$ 22.11M$ 15.09M
Cost of Revenue
$ -1.84M$ -6.19M$ 6.87M$ 6.33M$ 15.48M$ 9.80M
Gross Profit
$ -1.46M$ -1.43M$ -4.66M$ -3.55M$ 6.64M$ 5.29M
Operating Expense
$ 9.93M$ 23.63M$ 27.41M$ 28.13M$ 35.66M$ 44.74M
Operating Income
$ -7.81M$ -25.06M$ -32.07M$ -31.68M$ -29.03M$ -39.45M
Net Non Operating Interest Income Expense
$ -1.63M$ 556.81K$ -6.65K$ -4.92K$ -123.26K$ 87.64K
Other Income Expense
$ -410.45K$ 1.70M$ -2.52M$ -4.16M$ 1.65M$ -10.52K
Pretax Income
$ -25.02M$ -26.20M$ -34.60M$ -35.84M$ -27.50M$ -39.38M
Tax Provision
$ 2.00K$ 2.00K$ 796.00$ 2.40K$ 8.67K$ -369.34K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -9.31M$ -26.48M$ -45.83M$ -49.39M$ -27.51M$ -39.01M
Basic EPS
$ -0.15-$ -0.32$ -0.64$ -0.55$ -1.00
Diluted EPS
$ -0.15-$ -0.32$ -0.64$ -0.55$ -1.00
Basic Average Shares
$ 602.57M$ 149.85M$ 144.16M$ 77.57M$ 53.26M$ 39.09M
Diluted Average Shares
$ 602.57M$ 149.85M$ 144.16M$ 77.57M$ 53.26M$ 39.09M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 8.09M$ 17.44M$ 34.28M$ 34.46M$ 51.14M$ 54.54M
Net Income From Continuing And Discontinued Operation
$ -25.07M$ -26.48M$ -45.83M$ -49.39M$ -27.51M$ -39.01M
Normalized Income
$ -12.75M-$ -32.75M$ -32.78M$ -28.59M$ -39.00M
Interest Expense
--$ 6.65K$ 4.92K$ 123.26K$ 157.76K
$ -23.08M$ -26.75M$ -34.59M$ -35.84M$ -27.38M$ -39.22M
$ -21.83M$ -25.27M$ -33.16M$ -33.51M$ -24.44M$ -36.12M
Currency in USD

Adamis Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis